BrightGene Bio-Medical Technology Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Jiandong Yuan

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	8.9yrs
Eigentum des Geschäftsführers	32.2%
Durchschnittliche Amtszeit des Managements	8.9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.5yrs

Jüngste Management Updates

Recent updates

BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 47% Share Price Surge Not Quite Adding Up

May 21

BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Mar 01

Geschäftsführer

Jiandong Yuan (54 yo)

8.9yrs

Amtszeit

CN¥1,874,200

Vergütung

Mr. Jiandong Yuan serves as the Chairman and General Manager of BrightGene Bio-Medical Technology Co., Ltd. (Formerly known as Borui Biopharmaceutical (Suzhou) Co., Ltd.) and is its Director since August 2...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jiandong Yuan	Chairman & GM	no data	CN¥1.87m	32.24% CN¥ 4.8b
Yuanlai Zou	Financial Director	8.9yrs	CN¥460.50k	keine Daten
Nan Ding	Board Secretary	2.8yrs	CN¥417.60k	keine Daten
Zhengye Wang	Deputy General Manager	8.9yrs	CN¥915.70k	keine Daten
Kai Li	Deputy General Manager	8.9yrs	CN¥1.01m	keine Daten

8.9yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrenes Management: 688166Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (8.8 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jiandong Yuan	Chairman & GM	8.9yrs	CN¥1.87m	32.24% CN¥ 4.8b
Rong Xu	Independent Director	6.8yrs	CN¥100.00k	keine Daten
Zhang Li	Director	2.8yrs	CN¥626.60k	keine Daten
Fan Hang	Director	2.8yrs	CN¥814.60k	keine Daten
Yangqing Huang	Director	2.8yrs	CN¥854.00k	keine Daten
Lei Su	Director	2.8yrs	keine Daten	keine Daten
Zheng Yan	Independent Director	6.8yrs	CN¥100.00k	keine Daten
Xiaoqing Du	Independent Director	6.8yrs	CN¥100.00k	keine Daten
Xing He	Chairman of the Supervisory Board	4.2yrs	keine Daten	keine Daten
Yingxian Shen	Supervisor	6.8yrs	keine Daten	keine Daten
Wei Cha	Supervisor	2.8yrs	keine Daten	keine Daten
Dazhong Lv	Director	7.2yrs	keine Daten	keine Daten

5.5yrs

Durchschnittliche Betriebszugehörigkeit

46yo

Durchschnittliches Alter

Erfahrener Vorstand: 688166Die Vorstandsmitglieder gelten als erfahren (5.3 Jahre durchschnittliche Amtszeit).

BrightGene Bio-Medical Technology Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

BrightGene Bio-Medical Technology Co., Ltd., Annual General Meeting, May 20, 2024

BrightGene Bio-Medical Technology Co., Ltd., Annual General Meeting, May 20, 2024

Less than half of directors are independent

Recent updates

BrightGene Bio-Medical Technology Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 47% Share Price Surge Not Quite Adding Up

New minor risk - Profit margin trend

Investor sentiment improves as stock rises 17%

BrightGene Bio-Medical Technology Co., Ltd., Annual General Meeting, May 20, 2024

BrightGene Bio-Medical Technology Co., Ltd., Annual General Meeting, May 20, 2024

BrightGene Bio-Medical Technology Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Investor sentiment improves as stock rises 19%

BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Full year 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.58 in FY 2022)

BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) announces an Equity Buyback for CNY 20 million worth of its shares.

BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) announces an Equity Buyback for CNY 20 million worth of its shares.

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 21%

Third quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.21 in 3Q 2022)

Investor sentiment improves as stock rises 22%

Investor sentiment improves as stock rises 27%

First quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.60 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 2Q 2021)

Suzhou Hongbo Venture Capital Partnership agreed to acquire 2.42% stake in Caike (Suzhou) Biotechnology Co., Ltd. from BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) for CNY 20 million.

BrightGene Bio-Medical Technology Co., Ltd. announced that it expects to receive CNY 222.3054 million in funding

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.12 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.10 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.08 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.41 (vs CN¥0.30 in FY 2019)

BrightGene Bio-Medical Technology Co., Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day low: CN¥43.62

New 90-day low: CN¥48.50

New 90-day high: CN¥61.50

BrightGene Bio-Medical Technology Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020

New 90-day low - CN¥51.60

First half earnings released

BrightGene Bio-Medical Technology Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter